Blueprint Medicines Corporation - BPMC STOCK NEWS

Blueprint Medicines Corporation (NASDAQ: BPMC) reported first-quarter 2021 financial results, revealing total revenues of $21.6 million, a significant increase from $6.2 million in Q1 2020. Key revenue sources include $7.1 million from AYVAKIT/AYVAKYT and $1.8 million from GAVRETO. The company recorded a net loss of $99.7 million for Q1 2021, improving from a net loss of $111 million in Q1 2020. Blueprint continues to advance its pipeline, with multiple clinical trials set to initiate, including a potential U.S. approval for AYVAKIT for advanced systemic mastocytosis.

Blueprint Medicines Corporation (NASDAQ: BPMC) will host a live conference call on April 29, 2021, at 8:30 a.m. ET to discuss its first quarter 2021 financial results and provide a corporate update. Interested parties can join by dialing (855) 728-4793 domestically or (503) 343-6666 internationally, using conference ID 9292306. The call will also be accessible via a webcast on their website, with an archived version available for 30 days post-call. Blueprint Medicines focuses on developing precision therapies for cancer and blood disorders.

Blueprint Medicines Corporation (NASDAQ: BPMC) announced multiple presentations at the AACR Annual Meeting 2021, focusing on its systemic mastocytosis (SM) program, particularly the results from the PATHFINDER trial of AYVAKIT™ (avapritinib). Data revealed a 75% confirmed response rate among 32 patients, with median response time of two months. Additionally, BLU-263, a next-generation inhibitor, demonstrated a well-tolerated safety profile in healthy volunteers. The company is poised for a potential approval in advanced SM and plans to start the HARBOR study for BLU-263 in mid-2021.

Blueprint Medicines Corporation (BPMC) presented data at the virtual AACR Annual Meeting 2021, showcasing its precision therapy pipeline. The presentations included foundational preclinical data and clinical updates for AYVAKIT and BLU-263. Notably, BLU-701 and BLU-945 are being developed as fourth-generation EGFR inhibitors for NSCLC, with an IND application for BLU-945 cleared by the FDA. BLU-222, a selective CDK2 inhibitor, is also nominated for clinical development in early 2022. The company celebrates its 10th anniversary, reflecting on its expanding pipeline aimed at significant patient needs.

Blueprint Medicines Corporation (NASDAQ: BPMC) announced the grant of non-qualified stock options for 27,543 shares and restricted stock units (RSUs) for 13,792 shares to 14 new employees, effective April 1, 2021. This was part of the 2020 Inducement Plan, aimed at incentivizing new hires. The options have an exercise price of $97.95 per share, aligning with the closing stock price on the grant date. Both options and RSUs vest over a specified period, contingent on continued employment.

Blueprint Medicines Corporation (NASDAQ: BPMC) will hold a live conference call and webcast on April 12, 2021, at 8:00 a.m. ET. The event will review new data from its portfolio in precision oncology and hematology, which will also be showcased at the AACR Annual Meeting 2021 from April 9-14, 2021. Interested parties can join the call by dialing (855) 728-4793 (domestic) or (503) 343-6666 (international) using conference ID 5548976. An archived webcast will be available on their website for 30 days post-event.

Blueprint Medicines Corporation (NASDAQ: BPMC) announced its intent to present new data at the American Association for Cancer Research (AACR) Annual Meeting 2021, showcasing advancements in precision oncology and hematology. The presentations will focus on therapies for conditions such as systemic mastocytosis and non-small cell lung cancer. Notable highlights include preclinical data on BLU-701, a double-mutant EGFR inhibitor, and updates on various ongoing clinical trials. The company will also host an investor conference call to discuss these findings.

Blueprint Medicines Corporation (NASDAQ: BPMC) announced on March 5, 2021 that it granted non-qualified stock options for 15,474 shares and 7,736 restricted stock units (RSUs) to nine new employees, effective March 1, 2021. The grants are made under the 2020 Inducement Plan, aimed at individuals not previously employed by the company. The exercise price for the options is $100.13, equal to the closing stock price on the grant date. Vests will occur over a period, contingent on continued employment.

Blueprint Medicines Corporation (NASDAQ: BPMC) announced that the European Medicines Agency has validated its Type II variation marketing authorization application for AYVAKYT® (avapritinib) to treat advanced systemic mastocytosis (SM). This validation allows the commencement of the review process. AYVAKYT has received orphan medicinal product designation, highlighting its potential in treating this rare disease characterized by severe organ damage. The company is optimistic about bringing this precision therapy to European patients.